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Introduction
Metastatic breast cancer, the chronic form of the disease, is incurable. Over the last 2 decades, the median 5-year survival rate has continuously increased. The use of anthracyclines, and especially the use of taxanes, since the 1990s has had an important influence of this increase. The first taxane, paclitaxel, commonly used at dosages of 175 mg/m 2 every 3 weeks, showed promising activity in anthracyline-pretreated metastatic breast cancer. The main side effects are myelosupression, alopecia and neurological side effects. The necessity of cremophor in the paclitaxel formulation requires premedication with dexamethasone and H1/H2 inhibitors. Combinations of the drug with anthracyclines and antimetabolites or vinca alkaloids achieve higher remission rates and longer progressionfree survival (PFS), but do not change overall survival. The second taxane, docetaxel, developed some years later, showed higher tubulin affinity in vitro, but clinical results are very similar to paclitaxel. Docetaxel induces deep myelosupression, alopecia and also a form of neuropathy. Myelosuppression is associated with a high number of febrile neutropenia (FN) episodes. The use of colony stimulating factors decreases the rate of FN dramatically. Other side effects include nail changes and fluid retention syndrome. With docetaxel too, several combinations have been tested, showing similar results to paclitaxel but a higher number of severe side effects. At the end of the 1990s, weekly schedules of both taxanes were developed. In summary, many phase II studies showed that weekly taxane schedules are associated with a lower rate of side effects, but show similar (docetaxel) or even higher (paclitaxel) activity compared with 3-weekly schedules. Another important result was that premedication could be reduced without an increase in toxicity.
Weekly Paclitaxel
Phase II Studies Several phase II studies have been carried out in metastatic breast cancer, most of them with mixed cohorts of chemotherapy pretreated and non-pretreated patients. Dosages between 80 and 100 mg/m 2 where used in these studies. All studies showed a similar activity to the 3-weekly schedule, but at a decreased rate of side effects. Especially myelotoxicity was reduced in the weekly schedules. The response rates were between 22 and 53%. An overview of these studies is shown in table 1. In our own trial [1] , we used 90 mg/m 2 every week. Treatment was stopped after 12 weeks. Patients with extensive liver metastasis started with 60 mg/m 2 . Two thirds of the patients had been pretreated with anthracyclines as first-or secondline therapy. 26 (28%) patients responded (overall response rate (ORR): 31%, complete remission (CR): 3 patients). The median time to progression was 7.1 months for responders. Patients who achieved stable disease had a progression-free interval of 4.1 months. Perez et al. [2] were able to show that weekly paclitaxel is an option for older metastatic patients. In this trial with 212 patients, 34% were older then 65 years. Efficacy and toxicity were no different to younger women.
Phase III Studies
Sikov et al. [2, 3] conducted a phase III study which compared 3 different weekly schedules. In arm A, the weekly dosage was 150 mg/m 2 given 6 times every week with 2 weeks rest, followed by the same treatment again (arm A). In arm B, the same weekly dosage of paclitaxel was used, but patients received 2 treatments followed by 1 week rest. In the third arm, paclitaxel was given at 80 mg/m 2 every week for 15 weeks. In this study, the higher-dosage schedules produced no higher ORR but were associated with higher rates of toxicity compared to the 15-week schedule. Sparano et al. [4] compared weekly taxane regimens with the 3-weekly schedule, and paclitaxel with docetaxel in the adjuvant setting after 4 cycles of doxorubicin/cyclophosphamide (4×AC). No difference was found between any of the schedules or taxanes ( fig. 1 ).
Paclitaxel Combinations
Trastuzumab Different schedules of weekly treatment with paclitaxel in combination with trastuzumab were tested by several investi- (table 2) . In one trial, paclitaxel was given 12 weeks in combination with trastuzumab, followed by trastuzumab alone until progression. In other trials, paclitaxel and trastuzumab were given together until progression. Overall, the response rates ranged from 50 to 87%. Time to progression was approximately 9 months.
Bevacizumab
At the ASCO meeting 2005, Miller et al. [5] presented the first analysis of a randomized trial on first-line treatment of metastatic breast cancer, which compared weekly paclitaxel alone and in combination with bevacizumab. In this trial, the combination was more effective with respect to remission rates (14 vs. 29%) and PFS (6 vs. 11 months) ( fig. 2 ). Bevacizumab was given at 15 mg/kg every 3 weeks. The paclitaxel dose was 80 mg/m 2 every week. The main side effect was hypertension which could be controlled easily by standard medication.
Carboplatin-Paclitaxel
Platinum-taxane combinations have been evaluated by several groups [6, 7] . These combinations show similar efficacy to other combination therapies in metastatic breast cancer, including anthracycline-containing regimens. Their development was driven by preclinical data suggesting a synergistic effect of platinum salts and trastuzumab and demonstrating that these combinations are less cardiotoxic compared to anthracyclinecontaining combinations [8] .
Carboplatin-Paclitaxel-Trastuzumab
Burris et al. [9] were able to show that the combination of carboplatin, paclitaxel and trastuzumab is very effective in the treatment of metastatic breast cancer. Rowland et al. [10] compared a 3-weekly schedule of carboplatin, paclitaxel and trastuzumab with a weekly schedule. In this study, the weekly schedule was superior in response rate and time to progression as well 1-and 2-year survival (table 3) . The BCIRG 006 trial [11] compared a 3-weekly platinum-docetaxel-trastuzumab combination with 4×AC followed by docetaxel (×4)/ trastuzumab (×52). The platinum-containing combination was as good as the anthracycline-containing regimen in diseasefree survival (DFS), and less cardiotoxic ( fig. 3 ).
Conclusion
Weekly schedules of taxanes are characterized by good activity in metastatic breast cancer and a lower rate of side effects Seidman et al. [12] 100-120 100% ≥ 1 4 0 1 6 Marhenke et al. [13] 40-90 100% ≥ 2 (59% A, 38% T) 41 64 Mickiewicz et al. [14] 80-100 100% ≥ 1 (A) 61 49 Sikov et al. [3] 175 31% adjuvant 84 62 Lück et al. [1] 90 100% ≥ 2 met. regimens 31 86 Perez et al. [2] 80 35% 1st-line 22 212 ORR = Overall response rate; A= doxorubicin, T = docetaxel. [16] 90 (×2) > 2 60 90 Bangemann et al. [17] 80-175 (×2) 79% of patients (A, T) 50 90 Scholz et al. [18] 90 (12 weeks ×2) > 2 chemotherapies 50 24 including high-dose ORR = Overall response rate; A= doxorubicin, T = docetaxel. Lück/Vogel compared to the 3-weekly schedules. There is no difference in efficacy between the different taxanes, but paclitaxel was less toxic compared to docetaxel. Dose-dense therapies are only possible with paclitaxel. Weekly administration of paclitaxel is also the standard of care in adjuvant sequential anthracycline-containing chemotherapy regimens. The good tolerability and efficacy of weekly schedules make it seem logical to combine these therapies with new non-cytotoxic drugs, such as tyrosine kinase inhibitors or novel antibodies.
